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ABSTRACT
Children with acute lymphoblastic leukemia (ALL) receiving chemotherapy are at high risk for
developing hepatitis B infection. Protective effect of hepatitis B vaccination in children with
ALL in Indonesia has not been investigated yet. The aim of study was to determine the proportion
difference of anti-HBs seroprotection between children with ALL and without malignancy post
hepatitis B vaccination. We had conducted a case-control study from January to February 2012
at Dr. Sardjito General Hospital, Yogyakarta. We ascertained 1-15 years old children with ALL
receiving chemotherapy and without malignancy who had hepatitis B vaccination. Sixty seven
children were included in this study. Anti-HBs seroprotection level was measured using an
enzyme-linked immunosorbent assay (ELISA). The results were analyzed using Chi-square test.
Twenty one children (65.6%) with ALL and 13 children (37.1%) without malignancy showed
anti-HBs seroprotection. The difference was statistically significant with p-value of 0.020
(prevalence ratio [PR]=0.3; 95% CI=0.11-0.84). Both groups showed no significantly difference
of anti-HBs seroprotection according to either female gender, risk classification, or phase of
chemotherapy with p-value of 0.38 (PR =4; 95% CI=1.05-15.2), 0.248 (PR =3.37; 95%
CI=0.58-19.6) or 0.214, respectively. In conclusion, the proportion of anti-HBs seroprotection
in children with ALL is higher than those without malignancy.
ABSTRAK
Anak dengan leukemia limfoblastik akut (LLA) yang mendapat kemoterapi mempunyai risiko
tinggi terinfeksi hepatitis B. Efek proteksi vaksinasi hepatitis B yang pernah didapat sebelumnya
pada anak tersebut belum pernah diteliti di Indonesia. Tujuan penelitian ini adalah untuk
mengetahui perbedaan proporsi seroproteksi anti-HBs pada anak dengan LLA dengan anak yang
tidak mengalami keganasan pasca vaksinasi hepatitis B. Penelitian ini menggunakan rancangan
potong lintang dilakukan pada bulan Januari-Februari 2012 di RSUP Dr. Sardjito. Subyek penelitian
terdiri dari kelompok penderita LLA yang mendapat kemoterapi dan kelompok yang tidak
mengalami keganasan berusia 1-15 tahun yang pernah mendapat vaksinasi hepatitis B. Sebanyak
67 anak diikutsertakan dalam penelitian ini. Semua subyek penelitian diperiksa seroproteksi anti-
HBsnya menggunakan enzyme-linked immunosorbent assay (ELISA). Analisis hasil data
menggunakan uji Chi-square. Proporsi seroproteksi anti-HBs pada LLA sebesar 65,6% sedangkan
kelompok tanpa keganasan sebesar 37,1%. Perbedaan proporsi ini bermakna secara statistik
dengan nilai p=0,020 (rasio prevalensi [RP]=0,3; 95% CI=0,11-0,84). Tidak ada perbedaan
proporsi seroproteksi anti-HBs antara kedua kelompok berdasarkan jenis kelamin perempuan,
klasifikasi faktor risiko maupun fase kemoterapi dengan nilai p masing-masing adalah 0,38 (RP=4;
95% CI=1,05-15,2), 0,248 (RP=3,37; 95% CI=0,58-19,6) dan 0,214. Sebagai simpulan, proporsi
11
Yustinah et al, Anti-hepatitis B surface (anti-HBs) seroprotection in children with acute lymphoblastic leukemia
post hepatitis B vaccination in Indonesia
seroproteksi anti-HBs kelompok anak LLA pasca vaksinasi hepatitis B lebih tinggi dibandingkan
dengan kelompok anak tanpa keganasan.
Keywords : anti-HBs seroprotection level – post hepatitis B vaccination – acute lymphoblastic
leukemia – Indonesian cases
INTRODUCTION
Hepatitis B virus (HBV) infection is a
worldwide public health problem of major
concern.According to the most recent estimate,
6% or 378 million people worldwide are
chronically infected HBV. Hepatitis B virus is
estimated to be resposible for 500,000–700,000
deaths annually1 Indonesia is moderate-high
endemic country of hepatitis B with the
prevalence of hepatitis B surface antigen
(HBsAg) of 9.4% (2.5-36.1%).2
Hepatitis B virus can be transmitted both
vertically and horizontally, through sexual or
household contact, or by unsafe injections.
Vaccination against HBV is highly effective at
a relatively low cost. Therefore, World Health
Organization has been promoting the universal
use of this vaccination since 1991. The 3-dose
series of hepatitis B vaccine according to
Indonesian Immunization Program will lead to
an anti-HBs seroprotection response of at least
10 mIU/mL at almost 100% of infants, children
and adolescents.2 Hepatitis B vaccination can
induce immunologic memory for at least 15
years.3 However, between 5-10% population
have less or no response to hepatitis B
vaccination.
Children with malignancies have an
increased risk for vaccine-preventable diseases,
such as hepatitis B. Hepatitis B infection is a
major comorbidity of acute lymphoblastic
leukemia (ALL), which may affect the outcome
ofALLtreatment. Children withALLhave high
risk for developing hepatitis B infection due to
secondary immunosuppression to chemotherapy
and radiotherapy, multiple blood transfusions,
intravenous medication administration, and
invasive procedures.4 Either ALL and
chemotherapy can induce loss of humoral
immunity to viral vaccination antigens.5 This
study was conducted to evaluate the anti-HBs




This case-control study was conducted
from January to February 2012 at Dr. Sardjito
General Hospital, Yogyakarta, Indonesia. The
inclusion criteria were children aged 1-15 years
withALL receiving chemotherapy and without
malignancy, had hepatitis B vaccination
according to Indonesian Vaccination Program.
The exclusion criteria were history of jaundice,
chronic renal failure requiring hemodialysis,
HIV, chronic liver disease, relapseALL, obesity,
malnourishment, and unclear history of hepatitis
B vaccination.Additional exclusion criteria for
children without malignancy were receiving
systemic steroid of 2 mg/kg/day for >7 days or
1 mg/kg/day for >1 month or receiving other
immunosuppressive drugs. Written informed
consent was obtained from all parents for this
study.
Procedure of study
The study was using consecutive sampling.
The sample size was calculated using two-
proportion hypothesis test. Each group consisted
of 32 subjects. Interviews were performed to
obtain demographic data and previous medical
history. Vaccination status of patients was
obtained from interview and vaccination record
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form (Kartu Menuju Sehat). This study was
reviewed and approved by the Health Research
Ethics Committee of the Faculty of Medicine,
Universitas Gadjah Mada, Yogyakarta,
Indonesia.
Blood samples were taken from the
subjects by a trained paramedic. The hepatitis
B surface antibody (anti-HBs) level was
measured using an enzyme-linked immuno-
sorbent assay (ELISA). The anti-HBs level
10 mIU/mL was considered to be protective
level.
Statistical analysis
The proportions difference of anti-HBs
seroprotection between groups were evaluated
using Chi-square analysis. Prevalence ratios
and 95% confidence intervals (CI) were
calculated and p<0.05 was considered
significant.
RESULTS
In this study, we have analyzed 67 children
of whom 32 ALL group and 35 without
malignancy group. The average age were 71.6
months +34 months and 107 months +47 months
for ALL group and without malignancy group,
respectively. The ALL group consisted of 21
(65.6%) standard risks and 25 (78.1%) phases
of maintenance. The average duration of
chemotherapy was 11.5 months.
TABLE 1. Characteristics of subjects
The age range of this study was 1-15 years,
because the hepatitis B vaccination program
was introduced in all provinces in Indonesia
since 15 years ago.6 There was significantly
difference of age distribution (p = 0.001)
between ALL group and without malignancy
group (TABLE 1). It might due to wide range of
age causes the data become heterogeneous. Most
children in ALL group were aged > 10 years,
whereas most children in without malignancy
group were aged 5-15 years. There was no
significantly difference in sex distribution (p =
0.853) between two groups (TABLE 1).
The proportion of anti-HBs seroprotection
in ALL group (65.6%) was greater than those
in without malignancy group (37.1%), and the
difference was statistically significant with p-
value of 0.020 (PR=0.3; 95% CI=0.11-0.84)
(TABLE 2).
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TABLE 2. Anti-HBs seroprotection between ALL group and non-malignancy group
DISCUSSION
Our study clearly demonstrated that the
proportion of anti-HBs seroprotection was
significantly greater in ALL group than non-
malignancy group. Our result was different from
Alavi et al.7 that showed no significant
difference of anti-HBs seroprotection between
newly diagnosed ALL group and healthy
children group or between completed-
chemotherapy ALL group and healthy children
group.
Zignol et al.8 demonstrated that 56%
children with ALL still have anti-HBs
seroprotection after completion of
chemotherapy. Baytan et al.9 reported that
approximately 56% children withALLwho had
previous Hepatitis B vaccination revealed less
anti-HBs seroprotection during chemotherapy.
Fioredda et al.10 showed that 81% children with
ALL who completed chemotherapy within 10
months still have anti-HBs seroprotection.
Cheng et al.11 reported that 53.9% children with
ALL before chemotherapy showed anti-HBs
seroprotection and 30% of them still had anti-
HBs seroprotection after completing
chemotherapy.
Besides vaccination, the anti-HBs
seroprotection could be also stimulated by
hepatitis B infection. Children withALL have a
high risk for developing hepatitis B infection
due to multiple blood transfusions. There was
significantly association between the amount of
blood transfusion and the increase of hepatitis
B infection within 6 months of chemotherapy
(p = 0.03) and after chemotherapy completion
(p = 0.02). The prevalence of hepatitis B
infection in children with malignancy in Egypt
were 3.6%, 18.2%, and 34.2% at first diagnosis,
after 6 months of chemotherapy, and after
chemotherapy completion, respectively.12
Tavil et al.13 reported that the prevalence
of hepatitis B and hepatitis C infection in Turkey
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was 15% and 1.9% of whom most children were
high-risk group. The study also showed that
there was significant difference in number of
blood transfusions between high-risk group and
low-risk group (p <0.001). The anti-HBs
prevalence in blood donors in Indonesia was
8.8%.14 The prevalence of hepatitis B infection
in ALL children in Indonesia is not available
yet. The prevalence of anti-HBs in children with
malignancy in Malaysia is 22%.15
This study showed significantly difference
of anti-HBs seroprotection level between groups
according to age distribution, thus the age was
considered as a confounding factor. However
after adjustment, a significantly difference
between groups only shown by the aged 121-
180 months sub-group with p-value of 0.04
(PR=3.75; 95 % CI=1.62-8.68). The difference
might due to small samples (2 subjects) for the
aged 121-180 months sub-group. There were
no significant differences in anti-HBs
seroprotection between groups according to age
and gender with p-value of 0.262 and 0.375
(PR=1.5; 95% CI=0.58-4.13), respectively.
Zignol et al.8 reported the effect of
chemotherapy to development of polio, tetanus,
hepatitis B, measles, rubella, mumps in ALL
children who had previously vaccinated. The
study showed that young age (p=0.002; RR=7.1;
95% CI=2.1-23.8) and female gender (p=0.02;
RR=3.6; 95% CI=1.2-10.6) were predictor
factors for immunity response failure to measles
vaccine not others.
In the sub-group ALL analysis, there were
no significantly differences between groups
according to risk classification (p=0.248;
PR=3.37; 95% CI=0.58-19.6) and chemotherapy
phases (p=0.214). Van Tilburg et al.16 reported
that there was a decrease of specific antibodies
to diphtheria in the high-risk ALL group
compared to the medium-risk one (p = 0.033).
The range of anti-HBs level in the without
malignancy group was from < 2 to 545 mIU/mL
and the proportion of anti-HBs seroprotection
was 37.1%. The proportion of anti-HBs
seroprotection were 66.7%, 35.7%, and 26.7%
for the aged 12-60 months, 61-120 months and
121-180 months sub-group, respectively. The
results indicated that the proportion of anti-HBs
seroprotection in our subjects were low,
suggested that the hepatitis B vaccination does
not have a long-term protection and declines
with time.
Suraiyah et al.17 reported that the proportion
of anti-HBs seroprotection was 38% in children
aged 10-12 years after primary series of
hepatitis B immunization. But et al.18 showed
that the proportion of anti-HBs seroprotection
were 81.8%, 73%, and 68.2% for 10 years, 15
years and 20 years after vaccination, respecti-
vely. Other reports showed the proportion of
anti-HBs protection in 15-year period after
vaccination were 75.8% 19 and 68.82%. 20
Poovorawan et al.21 observed the proportion
of anti-HBs seroprotection in 20-year period
after vaccination was 60.5%.
Recently, Indonesia is the only country with
a national policy of Hepatitis B vaccination
using the UnijectTM method, including outside-
the-cold-chain for delivery of Hepatitis B
vaccine birth dose.22 Immunogenicity following
three doses of vaccine was not significantly
difference between infants receiving Hepatitis
B birth dose vaccine using UnijectTM method
and standard method.23
The significantly difference of anti-HBs
seroprotection according to age distribution
might due to lack of initial data of anti-HBs
among groups in this study. Anti-HBs
seroprotection will decrease with age. The
different results between our study and previous
reports because of difference in immunization
schedule, measurement of the anti-HBs levels,
and type and dose of chemotherapy used for
ALL.
The limitation of this study was most
participants (97%) did not bring Kartu Menuju
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Sehat (KMS). To reduce the bias, we inter-
viewed in detail about the schedule, frequency,
place, person who gave hepatitis B vaccination.
Other limitation was wide age-range subjects.
CONCLUSION
The proportion of anti-HBs seroprotection
in children withALLis higher than those without
malignancy. Furthermore, additional studies
with age-matched controls, narrow age-range
and complete initial data of anti-HBs are
necessary to clarify this result.
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